Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance-Reference-Cited by-同舟云学术

Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance

Published:2018-07 Issue:7 Volume:9 Page:
ISSN:2041-4889
Container-title:Cell Death & Disease
language:en
Short-container-title:Cell Death Dis

Author:

Che Yun,Wang Jingnan,Li Yuan,Lu Zhiliang,Huang Jianbing,Sun Shouguo,Mao Shuangshuang^ORCID,Lei Yuanyuan,Zang Ruochuan,Sun Nan,He Jie

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology

Link

http://www.nature.com/articles/s41419-018-0808-2.pdf

Reference38 articles.

1. Pennathur, A., Gibson, M. K., Jobe, B. A. & Luketich, J. D. Oesophageal carcinoma. Lancet (Lond., Engl.) 381, 400–412 (2013).

2. Rustgi, A. K. & El-Serag, H. B. Esophageal carcinoma. N. Engl. J. Med. 371, 2499–2509 (2014).

3. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer Statistics, 2017. CA Cancer J. Clin. https://doi.org/10.3322/caac.21387 (2017).

4. Lagergren, J., Smyth, E., Cunningham, D. & Lagergren, P. Oesophageal cancer. Lancet. https://doi.org/10.1016/s0140-6736(17)31462-9 (2017).

5. Chen, W. et al. Cancer statistics in China, 2015. CA Cancer J. Clin. https://doi.org/10.3322/caac.21338 (2016).

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long noncoding RNAs as potential targets for overcoming chemoresistance in upper gastrointestinal cancers;Biomedicine & Pharmacotherapy;2024-10

2. Advances in targeting cancer-associated fibroblasts through single-cell spatial transcriptomic sequencing;Biomarker Research;2024-07-29

3. Focus on Pancreatic Cancer Microenvironment;Current Oncology;2024-07-26

4. Therapeutic implications of signaling pathways and tumor microenvironment interactions in esophageal cancer;Biomedicine & Pharmacotherapy;2024-07

5. Rational design of HER2-targeted combination therapies to reverse drug resistance in fibroblast-protected HER2+ breast cancer cells;2024-05-19